Fresenius Medical Care AG & Co. KGaA FMS
22.69
0.34
1.52%
as of 25 Sep
- Market cap
- $11.9B
- P/E
- 11.8×
Follow FMS
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
19.22 | 12.47 | 11.87 | 11.72 |
P/S ratio |
0.71 | 0.62 | 0.55 | 0.54 | |
P/FCF ratio |
7.58 | 6.88 | 6.08 | 5.91 | |
P/Operating CF |
17.12 | 12.96 | 46.77 | 12.16 | |
P/B ratio |
0.95 | 0.86 | 0.75 | 0.77 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.98 | 0.89 | 0.86 | 0.85 | |
EV/EBITDA |
6.13 | 5.27 | 4.99 | 4.94 | |
EV/Operating CF |
7.51 | 6.54 | 6.18 | 5.95 | |
EV/FCF |
10.49 | 9.83 | 9.47 | 9.38 | |
Quick Ratio |
0.88 | 0.84 | 0.79 | 0.68 | |
Current Ratio |
1.36 | 1.26 | 1.20 | 1.07 | |
Net Debt/EBITDA |
5.90 | 5.62 | 7.89 | 7.41 | |
Debt/Assets |
22.23% | 23.56% | 23.95% | 24.18% | |
Debt/Equity |
0.49 | 0.51 | 0.53 | 0.56 | |
Asset Turnover |
0.60 | 0.62 | 0.63 | 0.63 | |
Operating CF/Net income |
2.80 | 2.89 | 1.93 | 3.93 | |
Capex/Depreciation |
(0.53) | (1.20) | (0.40) | (0.65) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.77% | 0.77% | 0.83% | 0.82% | |
Selling, General and Administrative Expense of Revenue |
14.44% | 15.50% | 16.24% | 15.14% | |
Intangible Assets out of Total Assets |
0.48 | 0.48 | 0.48 | 0.49 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.70) | (0.72) | (0.86) | (0.96) | |
Graham Number |
29.29 | 34.53 | 35.93 | 35.67 | |
Earnings Yield |
5.20% | 8.02% | 8.42% | 8.54% | |
Free Cash Flow Yield |
13.19% | 14.54% | 16.44% | 16.91% | |
Revenue per Share |
9.77 | 10.16 | 9.81 | 10.53 | |
Operating CF per Share |
1.54 | 1.84 | 0.48 | 1.86 | |
Capex per Share |
(0.40) | (0.78) | (0.40) | (0.51) | |
Free Cash Flow per Share |
1.14 | 1.06 | 0.08 | 1.35 | |
Cash per Share |
3.63 | 3.97 | 3.45 | 3.14 | |
Shareholders Equity per Share |
27.83 | 27.75 | 30.20 | 29.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
27.83 | 27.75 | 30.20 | 29.30 | |
Free Cash Flow |
664.35 | 615.48 | 46.70 | 726.32 | |
Working Capital |
2,413.76 | 1,870.54 | 1,613.32 | 595.00 | |
Capital Expenditures |
(234.06) | (454.85) | (218.85) | (272.21) | |
Net Current Asset Value |
(10,700.35) | (9,980.22) | (10,714.94) | (11,711.52) | |
EV/EBIT |
12.81 | 9.59 | 9.42 | 9.12 | |
Capex to Sales |
0.04 | 0.08 | 0.04 | 0.05 | |
Net Profit Margin |
5.63% | 6.27% | 2.55% | 4.49% | |
Price to Operating Income |
9.25 | 6.71 | 6.05 | 5.75 | |
| Other line items | |||||
Average Receivables |
3,716.73 | 3,640.01 | 4,066.39 | 3,848.67 | |
Average Payables |
960.72 | 1,005.24 | 992.97 | 945.16 | |
Average Inventory |
2,373.85 | 2,329.88 | 2,442.65 | 2,488.55 | |
Average Assets |
35,926.35 | 35,699.22 | 35,658.02 | 35,953.20 | |
Average Common Equity |
16,260.83 | 16,611.34 | 16,479.66 | 15,998.30 |
Columns are period end dates